Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Cara A. Rabik"'
Autor:
Alexandra McLean Stevens, Eric S. Schafer, Minhua Li, Maci Terrell, Raushan Rashid, Hana Paek, Melanie B. Bernhardt, Allison Weisnicht, Wesley T. Smith, Noah J. Keogh, Michelle C. Alozie, Hailey H. Oviedo, Alan K. Gonzalez, Tamilini Ilangovan, Alicia Mangubat-Medina, Haopei Wang, Eunji Jo, Cara A. Rabik, Claire Bocchini, Susan Hilsenbeck, Zachary T. Ball, Todd M. Cooper, Michele S. Redell
Publikováno v:
Cancers, Vol 15, Iss 4, p 1344 (2023)
Survival of pediatric AML remains poor despite maximized myelosuppressive therapy. The pneumocystis jiroveci pneumonia (PJP)-treating medication atovaquone (AQ) suppresses oxidative phosphorylation (OXPHOS) and reduces AML burden in patient-derived x
Externí odkaz:
https://doaj.org/article/2fa86c3a004b4e09b54a5c761db0cfc8
Autor:
Liora M. Schultz, Anne Eaton, Christina Baggott, Jenna Rossoff, Snehit Prabhu, Amy K. Keating, Christa Krupski, Holly Pacenta, Christine L. Philips, Julie-An Talano, Amy Moskop, Susanne H.C. Baumeister, Gary Douglas Myers, Nicole A. Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, Rachel Wilcox, Cara A. Rabik, Vanessa A. Fabrizio, Vasant Chinnabhandar, Michael Kunicki, Sharon Mavroukakis, Emily Egeler, Yimei Li, Crystal L. Mackall, Kevin J. Curran, Michael R. Verneris, Theodore W. Laetsch, Heather Stefanski
Publikováno v:
Journal of Clinical Oncology. 41:354-363
PURPOSE Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively,
Autor:
Kevin O. McNerney, Stephanie Si Lim, Alexandra Dreyzin, Anant Vatsayan, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Jenna Rossoff, Heather Emily Stefanski, Julie-An Talano, Amy Moskop, Steven Margossian, Michael R. Verneris, Doug Myers, Nicole Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, M. Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A Rabik, Susanne Baumeister, Vanessa A Fabrizio, Vasant Chinnabhandar, Yasemin Goksenin, Kevin J. Curran, Crystal Mackall, Theodore W Laetsch, Liora Michal Schultz
Publikováno v:
Transplantation and Cellular Therapy. 28:S473-S475
Autor:
Heather, Stefanski, Anne, Eaton, Christina, Baggott, Jenna, Rossoff, Michael R, Verneris, Amy K, Keating, Snehit, Prabhu, Holly L, Pacenta, Christine L, Phillips, Julie-An, Talano, Amy, Moskop, Steven P, Margossian, Gary Doug, Myers, Nicole A, Karras, Patrick A, Brown, Muna, Qayed, Michelle L, Hermiston, Prakash, Satwani, Christa, Krupski, Rachel, Wilcox, Cara A, Rabik, Vanessa A, Fabrizio, Vasant, Chinnabhandar, A Yasemin, Goksenin, Emily, Egeler, Sharon, Mavroukakis, Kevin J, Curran, Crystal L, Mackall, Theodore W, Laetsch, Liora M, Schultz
Publikováno v:
Blood advances, vol 7, iss 4
Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic leukemia; it is US Food and
Autor:
Audrey Mauguen, Snehit Prabhu, Christine L Phillips, Kevin J. Curran, Michael Kunicki, Prakash Satwani, Theodore W. Laetsch, Rachel Wilcox, Muna Qayed, Vasant Chinnabhandar, Crystal L. Mackall, Steven P. Margossian, Michael R. Verneris, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Julie-An An Talano, Emily Egeler, Gary Doug Myers, A. Yasemin Goksenin, Amy Moskop, Cara A Rabik, Holly L Pacenta, Amy K. Keating, Jenna Rossoff, Christa Krupski, Heather E. Stefanski, Patrick A. Brown, Nicole Karras, Jaap Jan Boelens, Sharon Mavroukakis, Liora M. Schultz
Publikováno v:
Blood advances, vol 6, iss 7
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5a5590ca98bdc6c2ccd6b052b9feb
https://escholarship.org/uc/item/6xt142fk
https://escholarship.org/uc/item/6xt142fk
Autor:
Michelle L. Hermiston, H. Placenta, Amy Moskop, Amy K. Keating, Heather E. Stefanski, Vanessa A Fabrizio, A. Goksenin, Christina Baggott, Jenna Rossoff, Christa Krupski, Vasant Chinnabhandar, Christine L Phillips, Cara A Rabik, Crystal L. Mackall, Muna Qayed, Kevin J. Curran, Liora M. Schultz, Michael R. Verneris, Michael Kunicki, Prakash Satwani, Steven P. Margossian, Jaap-Jan Boelens, Julie Talano, Nicole Karras, Patrick A. Brown, Rachel Wilcox, G.D. Myers, Audrey Mauguen, Snehit Prabhu, Theodore W. Laetsch
Publikováno v:
Cytotherapy. 23:S27-S29
Autor:
Michael Kunicki, Sharon Mavroukakis, Cara A Rabik, Christine L Phillips, Amy K. Keating, Jenna Rossoff, Christa Krupski, Rachel Wilcox, Amy Moskop, Adam Lane, Nicole Karras, Kevin J. Curran, A. Yasemin Goksenin, Crystal L. Mackall, Vasant Chinnabhandar, Emily Egeler, Heather E. Stefanski, Michelle L. Hermiston, Julie-An An Talano, Theodore W. Laetsch, Gary Doug Myers, Prakash Satwani, Snehit Prabhu, Christina Baggott, Steven P. Margossian, Patrick A. Brown, Muna Qayed, Vanessa A Fabrizio, Holly L Pacenta, Michael R. Verneris, Liora M. Schultz
Publikováno v:
Blood Advances
Key Points CD19 CAR therapy for R/R EM disease, particularly CNS, offers a beneficial option with similar toxicity and survival to BM disease.There was no increased cytokine release syndrome or neurotoxicity in patients with R/R EM disease, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5643a68fa7ec55f29728456a9d6f1876
https://escholarship.org/uc/item/1g83m8ch
https://escholarship.org/uc/item/1g83m8ch
Autor:
Steven P. Margossian, Rachel Wilcox, Michelle L. Hermiston, Holly L Pacenta, Heather E. Stefanski, Christina Baggott, Muna Qayed, Vanessa A Fabrizio, G.D. Myers, Snehit Prabhu, Vasant Chinnabhandar, Kevin J Curran, Michael R. Verneris, A. Yasemin Goksenin, Theodore W. Laetsch, Prakash Satwani, Christine L Phillips, Julie-An Talano, Crystal L. Mackall, Michael Kunicki, Liora M. Schultz, Amy Moskop, Nicole Karras, Patrick A. Brown, Cara A Rabik, Amy K. Keating, Jenna Rossoff, Christa Krupski
Publikováno v:
Blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d233911e1462c7c5bebdda65fda5c0
https://europepmc.org/articles/PMC8617436/
https://europepmc.org/articles/PMC8617436/
Autor:
Heather E. Stefanski, Liora M. Schultz, Yasemin Goksenin, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Nicole Karras, M. Christa Krupski, Vasant Chinnabhandar, Steven P. Margossian, Holly L Pacenta, Christine L Phillips, Douglas Myers, Kevin J. Curran, Lauren Pommert, Rachel Wilcox, Patrick A. Brown, Muna Qayed, Amy K. Keating, Amy Moskop, Erin H. Breese, Michael R. Verneris, Jenna Rossoff, Cara A Rabik, Crystal L. Mackall, Theodore W. Laetsch, Prakash Satwani, Snehit Prabhu, Julie-An Talano, Erin M. Guest
Publikováno v:
Blood advances, vol 6, iss 14
Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Admin
Autor:
Theodore W. Laetsch, Kevin J Curran, Michelle L. Hermiston, Prakash Satwani, Christina Baggott, Michael Kunicki, Crystal L. Mackall, Amy K. Keating, G.D. Myers, Vanessa A Fabrizio, Michael R. Verneris, Nicole Karras, Jenna Rossoff, Heather E. Stefanski, Christa Krupski, Christine L Phillips, Amy Moskop, Julie-An Talano, Rachel Wilcox, Steven P. Margossian, Holly L Pacenta, Snehit Prabhu, Cara A Rabik, Patrick A. Brown, Liora M. Schultz, A. Yasemin Goksenin, Muna Qayed, Vasant Chinnabhandar
Publikováno v:
Blood. 136:42-44
Introduction Chimeric antigen receptor (CAR) T cell therapy has been extremely efficacious in pediatric patients with multiply relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL) with overall remission rates of 81% by three months